The drug did not show any improvement in patients compared to placebo and failed to reach the expected results.
Epix suggested the outcome may have been affected by a higher-than-expected response in the placebo-treated patients. Epix also said they would now focus on the benefits of the drug for patients with depression.
“We are disappointed that treatment with PRX-00023 did not induce a statistically significant change in the HAM-A in patients with anxiety; however, we are encouraged by the data and will further analyze these results,” said Michael Kauffman CEO of Epix.
A preliminary review has indicated that PRX-00023 was well tolerated. Side effects, including impact on sexual function and sleep, in patients receiving PRX-00023, were similar to placebo.